Novo Nordisk A/S buy MoneyMoney
Summary
This prediction ended on 05.11.21 with a price of €100.38. The BUY prediction by MoneyMoney for Novo Nordisk A/S saw massive gains of 102.96%. Dividends of €11.99 are taken into consideration when calculating the performance. MoneyMoney has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | -1.611% | 3.135% | 15.880% | 15.652% |
iShares Nasdaq 100 | -0.500% | 0.775% | 20.054% | 32.402% |
iShares Nikkei 225® | -1.483% | 4.610% | 11.154% | -1.568% |
iShares S&P 500 | -0.501% | 1.914% | 21.016% | 37.314% |
Comments by MoneyMoney for this prediction
In the thread Novo Nordisk A/S diskutieren
NOVO NORDISK
Die Aktie ist in den letzten 12 Monaten sehr gut gelaufen .
Aufgrund der hohen Nachfrage , sowie guter Unternehmenszahlen bzw. eines guten Ausblicks gehe ich davon aus , dass die Aktie auch noch ein weiteres Potenzial aufweisen wird .
In the thread Trading Novo Nordisk A/S